Which cyclosporin formulation? [10]

Lancet

Volumn 348, Issue 9035, 1996, Pages 1175-1177

  Johnston, A ^a   Holt, D W ^a   Pollard, S ^a   Bennett, W M ^a   Filler, G ^a   Ehrich, J ^a   Gennery, A ^a   O'Sullivan, J ^a   O'Brien, C ^a   Dark, J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; CYCLOSPORIN;

AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; BIOAVAILABILITY; CHEMISTRY; NOTE; ABSORPTION; EMULSION;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ABSORPTION; EMULSIONS;

EID: 0030603306     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)65314-7     Document Type: Letter

References (5)

1. WM Benett A DeMattos DJ Norman MM Meyer A Olyaei Which cyclosporin formulation? Lancet 348 1996 205
2. DW Holt JT Marsden A Johnston M Bewick DH Taube Blood cyclosporin concentrations and renal allograft dysfunction BMJ 293 1986 1057 1059
3. A Lindholm BD Khan Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 1993 205 218
4. DW Holt EA Mueller JM Kovarik JB van Bree F Richard Kutz K Sandimmun neoral pharmacokinetics: impact of the new oral formulation Transplant Proc 27 1995 1434 1437
5. BD Kahan J Dunn C Fitts Reduced inter-and intra-subject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals Transplantation 59 1995 505 511